Answers are grounded in this paper and cite their sources.
n 2003, the US Food and Drug Administration (FDA) issued a boxed bolded warning for selective serotonin reuptake inhibitor (SSRI) use in children and adolescents based on findings from clinical trials conducted by developers. 1 Concerns were raised regarding the risk of suicidal thoughts and behaviors, which led to the potential avoidance of prescribing antidepressant medications to children, adolescents, and young adults.2 Questions remain regarding the potential of behavioral activation in this population.3 How Do Autism Spectrum Disorder Phenotypes Intersect With SSRI-Associated Activation?The empirical literature linked to individuals with autism spectrum disorder (ASD) has several nuanced findings.First, 2 meta-analyses
No takes yet. Share an insight, caveat, or question.
Mayank Gupta (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: